NO20092569L - Inhibitorer av Akt-aktivitet - Google Patents

Inhibitorer av Akt-aktivitet

Info

Publication number
NO20092569L
NO20092569L NO20092569A NO20092569A NO20092569L NO 20092569 L NO20092569 L NO 20092569L NO 20092569 A NO20092569 A NO 20092569A NO 20092569 A NO20092569 A NO 20092569A NO 20092569 L NO20092569 L NO 20092569L
Authority
NO
Norway
Prior art keywords
akt activity
inhibitors
akt
compounds
inhibit
Prior art date
Application number
NO20092569A
Other languages
English (en)
Norwegian (no)
Inventor
Michael J Kelly Iii
Mark E Layton
Philip E Sanderson
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20092569L publication Critical patent/NO20092569L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
NO20092569A 2006-12-06 2009-07-06 Inhibitorer av Akt-aktivitet NO20092569L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87319806P 2006-12-06 2006-12-06
US88066107P 2007-01-16 2007-01-16
US96787207P 2007-09-06 2007-09-06
PCT/US2007/024772 WO2008070041A2 (en) 2006-12-06 2007-12-03 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
NO20092569L true NO20092569L (no) 2009-07-06

Family

ID=39492823

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092569A NO20092569L (no) 2006-12-06 2009-07-06 Inhibitorer av Akt-aktivitet

Country Status (30)

Country Link
US (3) US7576209B2 (ja)
EP (1) EP2104669B1 (ja)
JP (2) JP4431636B1 (ja)
KR (1) KR101110598B1 (ja)
CN (1) CN101600706B (ja)
AR (1) AR064010A1 (ja)
AU (1) AU2007328286B2 (ja)
BR (1) BRPI0719580A2 (ja)
CA (1) CA2670760C (ja)
CL (1) CL2007003495A1 (ja)
CO (1) CO6190528A2 (ja)
CR (1) CR10851A (ja)
EA (1) EA016195B1 (ja)
EC (1) ECSP099376A (ja)
ES (1) ES2527567T3 (ja)
GE (1) GEP20125469B (ja)
GT (1) GT200900146A (ja)
HK (1) HK1137758A1 (ja)
HN (1) HN2009001112A (ja)
IL (2) IL198826A (ja)
MA (1) MA31027B1 (ja)
MX (1) MX2009006052A (ja)
NI (1) NI200900106A (ja)
NO (1) NO20092569L (ja)
NZ (2) NZ577470A (ja)
PE (1) PE20081341A1 (ja)
SV (1) SV2009003283A (ja)
TN (1) TN2009000224A1 (ja)
TW (1) TWI386410B (ja)
WO (2) WO2008070041A2 (ja)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100959771B1 (ko) * 2005-06-10 2010-05-28 머크 샤프 앤드 돔 코포레이션 Ａｋｔ 활성의 억제제
EP2120951A4 (en) * 2006-12-06 2012-02-15 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
AU2009255358A1 (en) * 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
US8536193B2 (en) * 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010002010A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
DE102008043724A1 (de) * 2008-11-13 2010-05-20 Biotronik Vi Patent Ag Erhöhung der Effizienz pharmazeutische Wirkstoffe-freisetzender Medizinprodukte durch Kombination mit einem Inhibitor des Transportproteins P-Glycoprotein
US20110288090A1 (en) * 2009-02-02 2011-11-24 Armstrong Donna J Inhibitors of AKT Activity
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2403339B1 (en) * 2009-03-06 2017-01-18 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102625807B (zh) 2009-09-08 2016-03-09 霍夫曼-拉罗奇有限公司 4-取代的吡啶-3-基-甲酰胺化合物和使用方法
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
CN103097384B (zh) * 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶
JP2013530250A (ja) 2010-07-13 2013-07-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 二環式ピリミジン化合物
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
EP2651949B1 (en) * 2010-12-16 2015-07-15 Bayer Intellectual Property GmbH Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
AU2012205601B2 (en) * 2011-01-11 2016-03-24 Novartis Ag Combination
TWI525097B (zh) 2011-04-06 2016-03-11 Taiho Pharmaceutical Co Ltd Novel imidazole and A compound or a salt thereof
AU2012238589B2 (en) 2011-04-07 2017-02-16 Bayer Intellectual Property Gmbh Imidazopyridazines as Akt kinase inhibitors
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
KR20190015600A (ko) 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013104611A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
CA2860723A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
CA2865202A1 (en) 2012-01-20 2013-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
RU2618423C2 (ru) 2012-07-02 2017-05-03 Тайхо Фармасьютикал Ко., Лтд. Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение
MX2015012274A (es) 2013-03-14 2016-06-02 Univ Maryland Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
JP6355724B2 (ja) 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
EP4265300A3 (en) 2013-10-01 2023-11-29 Novartis AG Combination
US20160317444A1 (en) * 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Liposomal Formulations for Allosteric AKT Inhibitors
WO2015116740A1 (en) 2014-01-28 2015-08-06 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
RU2016139697A (ru) 2014-03-12 2018-04-12 Новартис Аг Комбинация, содержащая ингибитор btk и ингибитор akt
US10022360B2 (en) * 2014-03-17 2018-07-17 Merck Sharp & Dohme Corp. Polymeric nanoparticles and methods of making and using same
CN111943962A (zh) 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
FR3033499A1 (fr) 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
US10793582B2 (en) 2015-10-22 2020-10-06 Mitsubishi Tanabe Pharma Corporation Bicyclic heterocyclic compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108426971B (zh) * 2018-03-09 2020-03-20 浙江中一检测研究院股份有限公司 一种快速检测水中微囊藻毒素的方法
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof
JP2023506768A (ja) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法
AU2021269065A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators and methods of use thereof
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379251B1 (en) * 2001-04-10 2008-07-09 Merck & Co., Inc. Inhibitors of akt activity
EP1379250A2 (en) * 2001-04-10 2004-01-14 Merck & Co., Inc. A method of treating cancer
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1496906A4 (en) * 2002-04-08 2006-05-03 Merck & Co Inc INHIBITORS OF AKT ACTIVITY
JP4394959B2 (ja) * 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
WO2003086394A1 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
AU2003226271B2 (en) * 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
DE60336576D1 (de) * 2002-10-30 2011-05-12 Merck Sharp & Dohme Hemmer der akt aktivität
ATE461179T1 (de) * 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
CN1809354A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
CA2522430A1 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
JP4679514B2 (ja) * 2003-04-24 2011-04-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
CA2542609C (en) * 2003-10-15 2013-06-04 Ube Industries, Ltd. Novel indazole derivatives
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
AU2005233584B2 (en) * 2004-04-09 2010-12-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN1942470A (zh) 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
WO2006036395A2 (en) * 2004-08-23 2006-04-06 Merck & Co., Inc. Inhibitors of akt activity
CA2588474A1 (en) * 2004-12-02 2006-06-29 Merck & Co., Inc. Inhibitors of akt activity
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006091395A2 (en) * 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
CN101155588A (zh) * 2005-04-12 2008-04-02 默克公司 Akt活性的抑制剂
KR100959771B1 (ko) 2005-06-10 2010-05-28 머크 샤프 앤드 돔 코포레이션 Ａｋｔ 활성의 억제제
EP1978966A4 (en) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use

Also Published As

Publication number Publication date
WO2008070041A2 (en) 2008-06-12
KR101110598B1 (ko) 2012-03-08
EP2104669A2 (en) 2009-09-30
SV2009003283A (es) 2009-11-09
CA2670760C (en) 2012-01-24
NZ577470A (en) 2011-11-25
NZ595829A (en) 2013-04-26
JP2009298786A (ja) 2009-12-24
TN2009000224A1 (en) 2010-10-18
WO2008070016A2 (en) 2008-06-12
IL198826A (en) 2010-11-30
WO2008070016A3 (en) 2008-09-12
US20080161317A1 (en) 2008-07-03
JP2010511703A (ja) 2010-04-15
ES2527567T3 (es) 2015-01-26
AU2007328286A2 (en) 2009-08-06
NI200900106A (es) 2010-01-20
GEP20125469B (en) 2012-04-10
US20090253734A1 (en) 2009-10-08
CN101600706B (zh) 2013-10-16
CL2007003495A1 (es) 2008-05-30
CA2670760A1 (en) 2008-06-12
GT200900146A (es) 2010-04-13
EA016195B1 (ru) 2012-03-30
EP2104669B1 (en) 2014-10-15
CO6190528A2 (es) 2010-08-19
HN2009001112A (es) 2011-07-22
US7576209B2 (en) 2009-08-18
TWI386410B (zh) 2013-02-21
AU2007328286B2 (en) 2011-01-20
MA31027B1 (fr) 2009-12-01
KR20090086095A (ko) 2009-08-10
CN101600706A (zh) 2009-12-09
AR064010A1 (es) 2009-03-04
IL205220A0 (en) 2011-07-31
CR10851A (es) 2009-06-25
HK1137758A1 (en) 2010-08-06
JP4431636B1 (ja) 2010-03-17
EA200970542A1 (ru) 2009-12-30
JP5364454B2 (ja) 2013-12-11
MX2009006052A (es) 2009-06-17
PE20081341A1 (es) 2008-10-19
TW200831509A (en) 2008-08-01
BRPI0719580A2 (pt) 2013-12-17
US8288407B2 (en) 2012-10-16
WO2008070041A3 (en) 2008-08-28
ECSP099376A (es) 2009-07-31
US20110160183A1 (en) 2011-06-30
AU2007328286A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
NO20092569L (no) Inhibitorer av Akt-aktivitet
NO20080150L (no) Inhibitorer av AKT-aktivitet
WO2006091395A3 (en) Inhibitors of akt activity
WO2006110638A3 (en) Inhibitors of akt activity
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
EP4285906A3 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
NO20081454L (no) Met-kinaseinhibitorer
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
WO2008033562A3 (en) Kinase inhibitor compounds
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
WO2006068796A3 (en) Inhibitors of akt activity
WO2006135604A3 (en) Inhibitors of checkpoint kinases
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
WO2007008502A3 (en) Inhibitors of checkpoint kinases
WO2007084135A3 (en) Inhibitors of checkpoint kinases
WO2007081808A3 (en) Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
WO2006074281A3 (en) Inhibitors of checkpoint kinases
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application